NCT00025363: Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma |
|
|
| Completed | 2 | 150 | US | vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, ifosfamide, Cyfos, Holoxan, IFF, IFX, IPP, etoposide, EPEG, VP-16, VP-16-213, tirapazamine, SR 4233, Tirazone, WIN 59075, filgrastim, G-CSF, Neupogen, sargramostim, GM-CSF, Leukine, Prokine, pharmacological study, pharmacological studies, pharmacogenomic studies, Pharmacogenomic Study, laboratory biomarker analysis | National Cancer Institute (NCI) | Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma | 10/07 | | | |
